Intractable Self-harm-What Support is Effective?

Status Recruiting

Clinical Trial Summary

The aim of this project is to evaluate a novel treatment program for individuals with intractable and lethal self-harm. The main questions are: 1: Is there, in individuals with intractable self-harm, a relevant improvement in daily functioning and is this improvement related to the provided interventions? The secondary research questions are: 2. Is there, in individuals with intractable self-harm, a relevant improvement in frequency and severity of self-harm? 3. Is there, in individuals with intractable self-harm, a relevant improvement in voluntary hospital admissions? 4. Is there, in individuals with intractable self-harm, a relevant improvement in compulsary hospital admissions? 5. Is there, in individuals with intractable self-harm, a relevant improvement in the use of medication pro re nata? 6. Is there, in individuals with intractable self-harm, a relevant improvement in cost-effectiveness related to the provided interventions?

Clinical Trial Description

Individuals with intractable, imminent and lethal self-harm often have multifaceted psychiatric symptoms, pervasive suffering, high mortality and a reduced level of daily functioning. Severe self-harm can lead to long periods of psychiatric inpatient care which can lead to reduced autonomy and aggravated self-harm. Effects of this care remain uncertain. The Swedish National Board of Welfare has provided National specialized medical care units for severe self-harm behaviour to three Swedish hospitals. In one of this hospitals, Region Skåne, the intervention will be consultation-based. Individuals with intractable self-harm will be offered an assessment and review of all medical records which will result in a individualized intervention plan. Interventions include further assessments and supporting the existing treatment providers, families or caregivers. Recurring network-meetings will occur every three months as well as at he end of the intervention. Data collection will include self-report measures as well as information from charts and national och regional registries. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06099561
Study type	Observational
Source	Region Skane
Contact	Magnus Nilsson, PhD
Phone	046-174925
Email	magnus.per.nilsson@skane.se
Status	Recruiting
Phase
Start date	September 1, 2023
Completion date	December 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06297824` - Feasibility of Emotion Regulation Group Therapy for Adolescent Self-Harm	N/A
Recruiting	`NCT04191122` - Community Outpatient Psychotherapy Engagement Service for Self-harm	N/A
Recruiting	`NCT06345053` - Presence of PTSD and Emotion Dysregulation Among Inpatients With Substance Use Disorder	N/A
Recruiting	`NCT05765864` - Self-harm Behaviour Among the Most At-risk Adolescents
Completed	`NCT04420546` - Using Implementation Intentions to Reduce Self-harm	N/A
Not yet recruiting	`NCT06019663` - Artificial Intelligence Self Harm Application	N/A
Not yet recruiting	`NCT05368701` - Developing a Smartphone-based App to Reduce Self-harm for CAMHS-treated Adolescents	N/A
Completed	`NCT04969718` - Suicide Prevention by Empowering Adolescents in Pakistan (SEPAK)	N/A
Recruiting	`NCT06315075` - Dialectical Behavior Therapy for Adolescents With Self-harm and Suicidal Behavior- an Open Trial	N/A
Withdrawn	`NCT05583279` - Dialectical Behavioral Therapy in Juvenile Justice	N/A
Completed	`NCT04005053` - Signatures of N-Ac for Non-Suicidal Self-Injury in Adolescents	Phase 2
Not yet recruiting	`NCT06290180` - Healing Lodge First Face Training Evaluation Study	N/A
Recruiting	`NCT05171192` - Culturally Adapted CMAP Plus LTP for Refugee Mothers With History of Self-harm in Pakistan	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.